New York, Jan 15, 2026, 11:01 ET — Regular session
- Johnson & Johnson shares slipped in early trading, underperforming the wider market rally.
- The drugmaker highlighted new Phase 3 data for Tecvayli in multiple myeloma.
- Investors are focused on the Jan. 21 earnings report, seeking guidance for 2026.
Johnson & Johnson shares dipped Thursday following fresh late-stage data release for its Tecvayli cancer drug, with investors also bracing for next week’s earnings report.
This update is crucial as Johnson & Johnson aims to expand the footprint of its newer drugs while shielding established products from pricing cuts and competition. Tecvayli plays a key role in the company’s blood cancer strategy, where even minor tweaks in labeling and timing can significantly impact sales momentum.
Investors are now wondering if the latest data boosts Johnson & Johnson’s argument to push Tecvayli into earlier lines of treatment. Using it sooner could open the door to more patients, but it also means facing tougher head-to-head comparisons and closer examination of side effects.
Johnson & Johnson announced topline data from the Phase 3 MajesTEC-9 trial showing Tecvayli (teclistamab) slashed the risk of disease progression or death by 71% compared to standard treatments in relapsed or refractory multiple myeloma—where the cancer has returned or stopped responding to previous therapies. The company also reported a 40% drop in the risk of death. An independent monitoring committee has recommended unblinding the study. “The MajesTEC-9 results reinforce the potential of TECVAYLI to transform treatment earlier,” said Roberto Mina of Emory University. 1
Separately, Johnson & Johnson announced the launch of a U.S. tablet and smartphone simulator app designed to assist plastic surgeons in planning breast augmentation consultations, under its MedTech division. “The Arbrea Breast Simulator Surgeon App for Mentor offers surgeons a straightforward digital tool,” said Alenka Brzulja, a global president within the unit. 2
Johnson & Johnson shares dipped roughly 0.6% to $217.22, slipping from an opening price of $218.23. During the session, the stock ranged from a low of $215.93 up to $218.60.
The S&P 500’s primary ETF gained roughly 0.4% during late morning trading.
The shift arrives as U.S. firms enter a packed earnings season, with investors focused sharply on guidance to gauge growth and margins for 2026. 3
Still, strong drug data doesn’t erase the usual hurdles: regulators could push for more comprehensive safety info before approving earlier use. Plus, some cancer immunotherapies carry serious risks that limit use outside specialist centers. Johnson & Johnson also remains mired in talc-related lawsuits, vowing to appeal after a U.S. jury slapped it with a $1.5 billion verdict in a recent case. 4
Johnson & Johnson is set to release its fourth-quarter 2025 results Wednesday, Jan. 21, with an earnings call kicking off at 8:30 a.m. ET. Investors will focus on the company’s 2026 outlook, the strength of drug and device sales, and any updates on regulatory timing related to the latest Tecvayli data. 5
